144 related articles for article (PubMed ID: 36074499)
1. Abemaciclib and Fulvestrant for Bilateral Choroidal Metastasis From Breast Carcinoma.
Barke MR; Agrawal KU; Shields CL
JAMA Ophthalmol; 2022 Oct; 140(10):1026-1028. PubMed ID: 36074499
[TBL] [Abstract][Full Text] [Related]
2. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature.
Gao HF; Zhang JS; Zhang QZ; Zhu T; Yang CQ; Zhang LL; Yang M; Ji F; Li JQ; Cheng MY; Niu G; Wang K
Front Endocrinol (Lausanne); 2021; 12():659537. PubMed ID: 34690920
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
[TBL] [Abstract][Full Text] [Related]
5. Abemaciclib: First Global Approval.
Kim ES
Drugs; 2017 Dec; 77(18):2063-2070. PubMed ID: 29128965
[TBL] [Abstract][Full Text] [Related]
6. [A Case of Palbociclib plus Fulvestrant‒Resistant Metastatic Breast Cancer That Responded to Abemaciclib plus Fulvestrant].
Kudo S; Makino T; Umetsu R; Tanaka T
Gan To Kagaku Ryoho; 2021 Apr; 48(4):519-521. PubMed ID: 33976037
[TBL] [Abstract][Full Text] [Related]
7. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Postoperative Pulmonary Metastasis of Breast Cancer with Complete Response by Abemaciclib plus Fulvestrant Therapy].
Higashi T; Ozawa K; Takei S; Takagi S; Yokoyama M; Mase K; Moriya T; Takeshita A; Mizutani M
Gan To Kagaku Ryoho; 2022 May; 49(5):581-583. PubMed ID: 35578939
[TBL] [Abstract][Full Text] [Related]
9. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
11. Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
Franzoi MA; Eiger D; Ameye L; Ponde N; Caparica R; De Angelis C; Brandão M; Desmedt C; Di Cosimo S; Kotecki N; Lambertini M; Awada A; Piccart M; Azambuja E
J Natl Cancer Inst; 2021 Apr; 113(4):462-470. PubMed ID: 32750143
[TBL] [Abstract][Full Text] [Related]
12. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
Hamilton E; Cortes J; Ozyilkan O; Chen SC; Petrakova K; Manikhas A; Jerusalem G; Hegg R; Huober J; Chapman SC; Lu Y; Hardebeck MC; Bear MM; Johnston EL; Martin M
Clin Breast Cancer; 2021 Jun; 21(3):181-190.e2. PubMed ID: 33148479
[TBL] [Abstract][Full Text] [Related]
13. Abemaciclib plus fulvestrant for breast cancer.
Stirrups R
Lancet Oncol; 2019 Nov; 20(11):e617. PubMed ID: 31587880
[No Abstract] [Full Text] [Related]
14. Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
El Rassy E; Bakouny Z; Assi T; Kattan J
Future Oncol; 2018 Apr; 14(9):891-895. PubMed ID: 29527939
[TBL] [Abstract][Full Text] [Related]
15. [Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].
Masuda N; Saji S; Kawaguchi T; Chen Y; Ohno S
Gan To Kagaku Ryoho; 2021 Dec; 48(12):1475-1483. PubMed ID: 34911915
[TBL] [Abstract][Full Text] [Related]
16. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
[TBL] [Abstract][Full Text] [Related]
17. Fatal acute hepatic failure secondary to thrombotic portal venopathy after commencing abemaciclib and fulvestrant treatment for advanced breast carcinoma: a unique autopsy finding.
Haynes HR; Mohan V; Mozayani B; Gallagher P
Breast J; 2021 Jul; 27(7):612-614. PubMed ID: 33987967
[TBL] [Abstract][Full Text] [Related]
18. Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer.
Abdel-Razeq H
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):1-9. PubMed ID: 29792845
[TBL] [Abstract][Full Text] [Related]
19. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Palumbo A; Lau G; Saraceni M
Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.
Tarantino P; Jin Q; Mittendorf EA; King TA; Curigliano G; Tolaney SM
Ann Oncol; 2022 Aug; 33(8):845-847. PubMed ID: 35525374
[No Abstract] [Full Text] [Related]
[Next] [New Search]
